文献速递白血病MDS 与骨髓增殖性肿瘤

细胞谱系水平靶向测序识别伴骨髓增生异常相关改变的急性髓系白血病

Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
PubMed 文献 · Blood Adv · 2018-01-01

该研究对13例MDS、16例临床诊断AML-MRC、4例疑似AML-MRC但临床诊断为AML-NOS及11例新发AML患者的三类细胞群进行54基因靶向测序,发现重叠突变在MDS和AML-MRC中显著富集,而原始细胞特异性非重叠突变在新发AML中富集,提示该方法有助于AML-MRC分类。

要点

  • 重叠突变(原始细胞与粒细胞共享)在MDS和AML-MRC中显著富集。
  • 排除DNMT3A、TET2和ASXL1后,重叠突变可有效区分MDS/AML-MRC与新增AML。
  • 原始细胞群≥3个突变有助于区分AML-MRC与MDS。

核心结论

  • 该方法有助于对临床可诊断的AML-MRC进行分类,并将临床诊断为AML-NOS的病例识别为潜在AML-MRC。
  • 需要额外的前瞻性研究来确认该方法的效用。

研究设计与样本

  • 对13例MDS、16例临床诊断AML-MRC、4例疑似AML-MRC但临床诊断为AML-NOS及11例新发AML患者样本的3个细胞群(粒细胞、原始细胞和T细胞组分)进行54基因靶向测序。

主要发现

  • 重叠突变(至少由原始细胞和粒细胞组分共享)在MDS和AML-MRC患者(包括疑似AML-MRC者)中显著富集,表明存在大量克隆性造血历史。
  • 原始细胞特异性非重叠突变在新发AML患者中显著富集。
  • 排除DNMT3A、TET2和ASXL1后,重叠突变的存在有效区分了MDS和AML-MRC或疑似AML-MRC患者与新发AML患者。
  • 原始细胞组分中≥3个突变有助于区分AML-MRC患者与MDS患者。

关键数值与推荐

  • 重叠突变定义为至少由原始细胞和粒细胞组分共享的突变。
  • 排除DNMT3A、TET2和ASXL1后的重叠突变用于区分MDS/AML-MRC与新增AML。
  • 原始细胞组分中≥3个突变用于区分AML-MRC与MDS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要额外的前瞻性研究来确认该方法的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a clonal myeloid neoplasm that typically arises de novo; however, some cases evolve from a preleukemic state, such as myelodysplastic syndrome (MDS). Such secondary AMLs and those with typical MDS-related clinical features are known as AMLs with myelodysplasia-related changes (AML-MRC). Because patients with AML-MRC have poor prognosis, more accurate diagnostic approaches are required. In this study, we performed targeted sequencing of 54 genes in 3 cell populations (granulocyte, blast, and T-cell fractions) using samples from 13 patients with MDS, 16 patients with clinically diagnosed AML-MRC, 4 patients with suspected AML-MRC but clinically diagnosed as AML not otherwise specified (AML-NOS), and 11 patients with de novo AML. We found that overlapping mutations, defined as those shared at least by the blast and granulocyte fractions, were significantly enriched in patients with MDS and AML-MRC, including those with suspected AML-MRC, indicating a substantial history of clonal hematopoiesis. In contrast, blast-specific nonoverlapping mutations were significantly enriched in patients with de novo AML. Furthermore, the presence of overlapping mutations, excluding DNMT3A, TET2, and ASXL1, effectively segregated patients with MDS and AML-MRC or suspected AML-MRC from patients with de novo AML. Additionally, the presence of ≥3 mutations in the blast fraction was useful for distinguishing patients with AML-MRC from those with MDS. In conclusion, our approach is useful for classifying clinically diagnosable AML-MRC and identifying clinically diagnosed AML-NOS as latent AML-MRC. Additional prospective studies are needed to confirm the utility of this approach.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yokoyama K, Shimizu E, Yokoyama N, et al. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes. Blood Adv. 2018. PMID: 30282643. doi:10.1182/bloodadvances.2017010744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。